ITMCTR2000004106尚未招募1 期
Difference of PTEN / PI3K / Akt signaling pathway between colorectal damp heat syndrome and spleen stomach weakness syndrome in patients with colon adenoma
Shanghai Traditional Chinese MedicineIntegrated Hospital0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational study
入排标准
- 年龄范围
- 18 至 75（—）
- 性别
- All
入选标准
- •1. according to the diagnosis of colon adenoma: according to the jnet classification of 2A under endoscopy, the pathological diagnosis was in accordance with low-grade intraepithelial neoplasia of adenoma;
- •2. TCM syndrome differentiation was consistent with large intestine damp heat syndrome or spleen and stomach weakness syndrome;
- •3. aged 18-75 years old;
- •4. signed informed consent and voluntarily entered the trial.
- •Large intestine dampness heat syndrome: main symptoms:
- •(1) stool frequency increased, diarrhea is more smelly, or pus blood, or such as water injection;
- •(2) there are urgent afterweight, anus burning;
- •(3) red tongue, yellow or yellow greasy or yellow dry.
- •Secondary symptoms:
- •(1) abdominal pain refused to press, fullness and discomfort;
- •(2) Fanke drink or do not want to drink;
- •(3) constipation or loose stool;
- •(4) hot and sweating;
- •(5) short red urine;
- •(6) head and body weight;
- •(7) pulse slip number.
- •Syndrome determination: 2 main symptoms + 3 secondary symptoms, Spleen and stomach deficiency syndrome: main symptoms:
- •(1) abdominal distension, less intake, after eating, bloating;
- •(2) loose and thin stool;
- •(3) mental fatigue and fatigue;
- •(4) shortness of breath and lazy speech;
- •(5) light tongue, thin and white fur.
- •Secondary symptoms:
- •(1) continuous abdominal pain, from time to time, like warming and pressing;
- •(2) cold shape and cold limbs;
- •(3) no Chinese complexion;
- •(4) poor appetite;
- •(5) loose stool;
- •(6) fat tongue;
- •(7) fine pulse.
- •Syndrome determination: 2 main symptoms + 3 secondary symptoms
排除标准
- •(1) patients under 18 years old or over 75 years old, pregnant and lactating women;
- •(2) pathological diagnosis of non adenomatous low-grade intraepithelial neoplasia;
- •(3) colonoscopy contraindications or other reasons can not be performed colonoscopy;
- •(4) enteroscopy diagnosis of enteritis, intestinal ulcer, non intestinal polyps;
- •(5) digestive tract tumors;
- •(6) Combined with cardiovascular and cerebrovascular, liver and kidney, blood system and other serious primary diseases, mental patients;
- •(7) syndrome differentiation of traditional Chinese medicine has concurrent syndrome.
研究者
相似试验
已完成
不适用
p-AKT Expression on Clinical Outcomes in Malignant LymphomaMalignant LymphomaP13K-AKT Pathway DeregulationNCT01789060Samsung Medical Center262
尚未招募
1 期
Based on PI3K/AKT/HIF-1 signaling pathway, to explore the clinical efficacy and mechanism of Zuoguiyin intervention in oxidative stress in the treatment of premature ovarian insufficiencyPremature ovarian insufficiencyITMCTR2023000069Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
已完成
不适用
The Relationship of Phosphatidylinositol 3 Kinase Expression to Grading and Metastasis in Luminal Subtype Breast Cancer Patientspatients with the luminal subtype breast cancermetastasisphosphatidylinositol 3-kinaseluminal subtypebreast cancerTCTR20240615001Self funding74
已完成
不适用
PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with hormone receptor-positive advanced metastatic breast cancer, who have progressed on anastrozole or letrozoleadvanced metastatic breast cancer10006291breast cancerNL-OMON46855Vrije Universiteit Medisch Centrum175
进行中（未招募）
1 期
Analysis of tumor tissue and circulating genetic material in the blood to obtain further insight in the effectiveness of everolimus when combined with exemestane.A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with advanced metastatic breast cancer, who have progressed on anastrozole or letrozole.Hormone receptor-positive advanced metastatic breast cancer in postmenopausal patients who have progressed on anastrozole or letrozole.EUCTR2013-004120-11-NLVU University Medical Center175